-
Article
Open AccessThe role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer
Pre-treatment tumour-associated lymphocytes (TILs) and stromal lymphocytes (SLs) are independent predictive markers of future pathological complete response (pCR) in HER2-positive breast cancer. Whilst studies...
-
Article
HER2-family signalling mechanisms, clinical implications and targeting in breast cancer
Approximately 20 % of human breast cancers (BC) overexpress HER2 protein, and HER2-positivity is associated with a worse prognosis. Although HER2-targeted therapies have significantly improved outcomes for HER...
-
Article
A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib
The PI3K pathway is a key mechanism of trastuzumab resistance, but early attempts to indirectly target this pathway with mTOR inhibitors have had limited success. We present the results of a preclinical study ...
-
Article
Open AccessMembrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis
Malignant melanoma, generally described as incurable, is notoriously refractory to chemotherapy. The mechanisms contributing to this have not yet been defined and the contributions of drug efflux pumps, implic...
-
Article
Open AccessContribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells
Hypoxia is as an indicator of poor treatment outcome. Consistently, hypoxic HCT116 colorectal cancer cells are resistant to oxaliplatin, although the mechanistic basis is unclear. This study sought to investig...
